Clinical Trial Update: Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia [Phase 4]

View source ↗

Summary

Pilot Phase 4 trial evaluating atomoxetine to enhance cognition in schizophrenia; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Research Foundation for Mental Hygiene, Inc. | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED